MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer.
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MITO 35a
- 25 Aug 2021 New trial record